Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Trial of Palbociclib in Combination With Trastuzumab and Endocrine Therapy in Patients With Previously-treated Locally Advanced or Metastatic HER2-positive Breast Cancer (PATRICIA II)

Next Previous
Search
Trial Profile

A Phase II Trial of Palbociclib in Combination With Trastuzumab and Endocrine Therapy in Patients With Previously-treated Locally Advanced or Metastatic HER2-positive Breast Cancer (PATRICIA II)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Palbociclib (Primary) ; Trastuzumab (Primary) ; Trastuzumab (Primary) ; Anastrozole; Capecitabine; Docetaxel; Eribulin; Exemestane; Fulvestrant; Gemcitabine; Letrozole; Paclitaxel; Tamoxifen; Taxanes; Trastuzumab emtansine; Vinorelbine
  • Indications Adenocarcinoma; Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Acronyms PATRICIA II; SOLTI-1303 PATRICIA II

    • Most Recent Events

    • 04 Jun 2024 Results (At data cut-off, 264 ) from cohort C, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 17 Apr 2024 Status changed from active, no longer recruiting to completed.
    • 06 Oct 2023 Planned End Date changed from 1 Aug 2023 to 1 Dec 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top